WINTON GROUP Ltd Invests $767,000 in Eton Pharmaceuticals, Inc. $ETON

WINTON GROUP Ltd acquired a new position in shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON) in the 3rd quarter, HoldingsChannel.com reports. The institutional investor acquired 35,304 shares of the company’s stock, valued at approximately $767,000.

Other hedge funds have also bought and sold shares of the company. Russell Investments Group Ltd. lifted its holdings in Eton Pharmaceuticals by 202.9% in the third quarter. Russell Investments Group Ltd. now owns 54,865 shares of the company’s stock valued at $1,192,000 after buying an additional 36,753 shares during the period. Jefferies Financial Group Inc. acquired a new stake in Eton Pharmaceuticals during the 3rd quarter worth about $1,922,000. Lumbard & Kellner LLC acquired a new stake in Eton Pharmaceuticals during the 3rd quarter worth about $3,831,000. GSA Capital Partners LLP bought a new position in shares of Eton Pharmaceuticals in the 3rd quarter worth about $321,000. Finally, Vanguard Group Inc. raised its position in shares of Eton Pharmaceuticals by 2.4% in the 3rd quarter. Vanguard Group Inc. now owns 1,344,115 shares of the company’s stock worth $29,208,000 after acquiring an additional 31,942 shares in the last quarter. Institutional investors own 27.86% of the company’s stock.

Eton Pharmaceuticals Stock Up 0.2%

Shares of NASDAQ ETON traded up $0.03 during trading on Friday, hitting $19.05. 16,347 shares of the company traded hands, compared to its average volume of 264,491. The firm has a market capitalization of $510.92 million, a price-to-earnings ratio of -75.80 and a beta of 1.19. The business’s fifty day moving average is $16.31 and its 200 day moving average is $17.27. The company has a debt-to-equity ratio of 1.19, a quick ratio of 1.25 and a current ratio of 1.63. Eton Pharmaceuticals, Inc. has a fifty-two week low of $11.09 and a fifty-two week high of $23.00.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the company. HC Wainwright boosted their price objective on Eton Pharmaceuticals from $35.00 to $37.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. Zacks Research upgraded Eton Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Thursday, January 1st. Wall Street Zen lowered Eton Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, December 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Eton Pharmaceuticals in a report on Thursday, January 22nd. Finally, Craig Hallum raised their price objective on shares of Eton Pharmaceuticals from $29.00 to $30.00 and gave the stock a “buy” rating in a research report on Tuesday, March 3rd. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Eton Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $31.00.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.